BriaCell Activates a Clinical Site in Florida for Phase IIa Study of Its Lead Candidate in Advanced Breast Cancer
BriaCell Therapeutics Corp. ("BriaCell"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce that Sylvester Comprehensive Cancer Center at the University of Miami is now actively screening and enrolling patients in the ongoing, multicenter, Phase IIa study of Bria-IMT™ in advanced breast cancer. Dr. Carmen Julia Calfa, a Board-Certified breast medical oncologist, will act as the clinical site's principal investigator. Dr. Calfa will work closely with Cancer Insight, LLC., BriaCell's contract research organization, to...
View full press release